

U.S.S.N. 10/041,958
FILED: JANUARY 2, 2002
AMENDMENT AND RESPONSE TO OFFICE ACTION

In the Claims

26. (currently amended) A dosage formulation comprising an effective amount of human or humanized monoclonal antibodies, the antibodies consisting of antibodies neutralizing Shiga like toxin II *in vivo*, wherein the antibodies are specifically reactive with a single subunit of the Shiga like toxin II produced by *Escherichia coli* which causes hemolytic uremic syndrome, to prevent or treat hemolytic uremic syndrome in a human.

27. (previously presented) The dosage formulation of claim 26, wherein the antibodies are human monoclonal antibodies.

28. (previously presented) The dosage formulation of claim 26, wherein the antibodies are produced by recombinant DNA methodology.

29. (previously presented) The dosage formulation of claim 26, wherein the antibodies are chimeric monoclonal antibodies.

30. (previously presented) The dosage formulation of claim 26, wherein the antibodies bind to the alpha subunit of the Shiga like toxin II.

31. (previously presented) The dosage formulation of claim 26 wherein the antibodies are effective to prevent neurological signs of hemolytic uremic syndrome or lesions, wherein the neurological signs or lesions are selected from the group consisting of bloody diarrhea, acute renal failure, cerebral hemorrhaging, bacterial shedding into feces, bacterial lesions, paddling, head-pressing, ataxia, convulsions and wasting.

32. (previously presented) The dosage formulation of claim 26, wherein the antibodies are effective to prolong survival.

U.S.S.N. 10/041,958

FILED: JANUARY 2, 2002

AMENDMENT AND RESPONSE TO OFFICE ACTION

33. (currently amended) The dosage formulation of claim 26, ~~in a pharmaceutically acceptable carrier for injection~~, wherein the antibodies bind to the beta subunit of the Shiga like toxin II.

34. (previously presented) The dosage formulation of claim 26 equivalent to 4 ml serum from an animal immunized with Shiga-like toxin II/kg body weight.

35. (previously presented) The dosage formulation of claim 26 producing a serum level of anti-Shiga toxin II antibodies of at least 0.5 micrograms/ml.

36. (previously presented) The dosage formulation of claim 26 equivalent to a dosage of 3 mg human monoclonal antibody to Shiga-like toxin II administered to a newborn pig.